[1]
Maloney NJ, Tegtmeyer K, Zhao J, Worswick S. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis. Journal of drugs in dermatology : JDD. 2019 Oct 1:18(10):. pii: S1545961619P1053X. Epub
[PubMed PMID: 31603635]
[2]
Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin therapy letter. 2017 Nov:22(6):1-4
[PubMed PMID: 29091379]
Level 3 (low-level) evidence
[3]
Napolitano M, Di Guida A, Nocerino M, Fabbrocini G, Patruno C. The emerging role of dupilumab in dermatological indications. Expert opinion on biological therapy. 2021 Nov:21(11):1461-1471. doi: 10.1080/14712598.2021.1907341. Epub 2021 Mar 30
[PubMed PMID: 33769900]
Level 3 (low-level) evidence
[4]
Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert review of clinical pharmacology. 2018 May:11(5):467-474. doi: 10.1080/17512433.2018.1449642. Epub 2018 Mar 20
[PubMed PMID: 29557246]
[5]
Senner S, Seegräber M, Frey S, Kendziora B, Eicher L, Wollenberg A. Dupilumab for the treatment of adolescents with atopic dermatitis. Expert review of clinical immunology. 2020 Jul:16(7):641-650. doi: 10.1080/1744666X.2020.1801420. Epub 2020 Aug 13
[PubMed PMID: 32720530]
[6]
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet (London, England). 2016 Jul 2:388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27
[PubMed PMID: 27130691]
Level 1 (high-level) evidence
[7]
Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. The journal of allergy and clinical immunology. In practice. 2020 Feb:8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12
[PubMed PMID: 31521831]
[8]
Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T, Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A, Djukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H, Vitary C, Bush A. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. The European respiratory journal. 2020 Jan:55(1):. pii: 1900588. doi: 10.1183/13993003.00588-2019. Epub 2020 Jan 2
[PubMed PMID: 31558662]
[9]
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nature medicine. 2023 May:29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4
[PubMed PMID: 37142763]
Level 1 (high-level) evidence
[10]
Cao P, Xu W, Jiang S, Zhang L. Dupilumab for the treatment of prurigo nodularis: A systematic review. Frontiers in immunology. 2023:14():1092685. doi: 10.3389/fimmu.2023.1092685. Epub 2023 Jan 20
[PubMed PMID: 36742321]
Level 1 (high-level) evidence
[11]
Nhu QM, Aceves SS. Current state of biologics in treating eosinophilic esophagitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2023 Jan:130(1):15-20. doi: 10.1016/j.anai.2022.10.004. Epub 2022 Oct 12
[PubMed PMID: 36243282]
[12]
Al-Horani RA, Chiles R. First Therapeutic Approval for Eosinophilic Esophagitis. Gastroenterology insights. 2022 Sep:13(3):238-244. doi: 10.3390/gastroent13030024. Epub 2022 Jul 30
[PubMed PMID: 35967984]
[13]
Aceves SS, Dellon ES, Greenhawt M, Hirano I, Liacouras CA, Spergel JM. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2023 Mar:130(3):371-378. doi: 10.1016/j.anai.2022.12.014. Epub 2022 Dec 13
[PubMed PMID: 36521784]
[14]
Kulkarni M, Rohan CA, Travers JB, Serrao R. Long-Term Efficacy of Dupilumab in Alopecia Areata. The American journal of case reports. 2022 Jun 21:23():e936488. doi: 10.12659/AJCR.936488. Epub 2022 Jun 21
[PubMed PMID: 35726185]
Level 3 (low-level) evidence
[15]
van der Schaft J, Thijs JL, de Bruin-Weller MS, Balak DMW. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? Current opinion in allergy and clinical immunology. 2019 Aug:19(4):341-349. doi: 10.1097/ACI.0000000000000551. Epub
[PubMed PMID: 31145194]
Level 3 (low-level) evidence
[16]
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM, BOREAS Investigators. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. The New England journal of medicine. 2023 Jul 20:389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21
[PubMed PMID: 37272521]
[17]
Zhang Y, Xu Q, Chen L, Chen J, Zhang J, Zou Y, Gong T, Ji C. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. Frontiers in immunology. 2021:12():738907. doi: 10.3389/fimmu.2021.738907. Epub 2021 Oct 14
[PubMed PMID: 34721404]
[18]
D'Ippolito D, Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P & T : a peer-reviewed journal for formulary management. 2018 Sep:43(9):532-535
[PubMed PMID: 30186024]
[19]
Hurdayal R, Brombacher F. Interleukin-4 Receptor Alpha: From Innate to Adaptive Immunity in Murine Models of Cutaneous Leishmaniasis. Frontiers in immunology. 2017:8():1354. doi: 10.3389/fimmu.2017.01354. Epub 2017 Nov 10
[PubMed PMID: 29176972]
[20]
Harb H, Chatila TA. Mechanisms of Dupilumab. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2020 Jan:50(1):5-14. doi: 10.1111/cea.13491. Epub 2019 Sep 30
[PubMed PMID: 31505066]
[21]
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. The Journal of allergy and clinical immunology. 2019 Jan:143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5
[PubMed PMID: 30194992]
[22]
Ghani H, Jamgochian M, Pappert A, Rahman R, Cubeli S. The Psychosocial Burden Associated With and Effective Treatment Approach for Atopic Dermatitis: A Literature Review. Journal of drugs in dermatology : JDD. 2021 Oct 1:20(10):1046-1050. doi: 10.36849/JDD.6328. Epub
[PubMed PMID: 34636512]
[24]
Holm JG, Agner T, Sand C, Thomsen SF. Dupilumab for prurigo nodularis: Case series and review of the literature. Dermatologic therapy. 2020 Mar:33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16
[PubMed PMID: 31917498]
Level 2 (mid-level) evidence
[25]
Bosma AL, Gerbens LAA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. Clinical and experimental dermatology. 2021 Aug:46(6):1089-1092. doi: 10.1111/ced.14725. Epub 2021 Jun 4
[PubMed PMID: 33969522]
Level 2 (mid-level) evidence
[26]
Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, Deniz Y, Ruddy M, Laws E, Patel N, Weinreich DM, Yancopoulos GD, Amin N, Mannent LP, Lederer DJ, Hardin M, Liberty Asthma VOYAGE Investigators. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. The New England journal of medicine. 2021 Dec 9:385(24):2230-2240. doi: 10.1056/NEJMoa2106567. Epub
[PubMed PMID: 34879449]
[27]
Silverberg JI, Lynde CW, Abuabara K, Patruno C, de Benedetto A, Zhang H, Thomas RB, Bégo-Le-Bagousse G, Khokhar FA, Vakil J, Marco AR, Levit NA. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials. American journal of clinical dermatology. 2023 May:24(3):469-483. doi: 10.1007/s40257-022-00754-4. Epub 2023 Feb 20
[PubMed PMID: 36808602]
Level 1 (high-level) evidence
[28]
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. The New England journal of medicine. 2014 Jul 10:371(2):130-9. doi: 10.1056/NEJMoa1314768. Epub
[PubMed PMID: 25006719]
[29]
Aszodi N, Thurau S, Seegräber M, de Bruin-Weller M, Wollenberg A. Management of dupilumab-associated conjunctivitis in atopic dermatitis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2019 May:17(5):488-491. doi: 10.1111/ddg.13809. Epub 2019 Mar 15
[PubMed PMID: 30873757]
[30]
Nitro L, Bulfamante AM, Rosso C, Saibene AM, Arnone F, Felisati G, Pipolo C. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review. Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. 2022 Jun:42(3):199-204. doi: 10.14639/0392-100X-N1911. Epub
[PubMed PMID: 35880360]
Level 3 (low-level) evidence
[31]
Tameez Ud Din A, Malik I, Arshad D, Tameez Ud Din A. Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for? Cureus. 2020 Apr 6:12(4):e7565. doi: 10.7759/cureus.7565. Epub 2020 Apr 6
[PubMed PMID: 32382467]
[32]
Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, Pink AE. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. The British journal of dermatology. 2019 Nov:181(5):1068-1070. doi: 10.1111/bjd.18031. Epub 2019 Jul 18
[PubMed PMID: 31017658]
Level 2 (mid-level) evidence
[33]
Martinez-Cabriales SA, Kirchhof MG, Constantinescu CM, Murguia-Favela L, Ramien ML. Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020. American journal of clinical dermatology. 2021 Jul:22(4):443-455. doi: 10.1007/s40257-021-00607-6. Epub 2021 Jun 2
[PubMed PMID: 34076879]
Level 3 (low-level) evidence
[34]
Fritz AL, Lacy FA, Morrell DS. Angioedema: A potential complication of dupilumab in atopic dermatitis. Pediatric dermatology. 2021 Jan:38(1):237-238. doi: 10.1111/pde.14434. Epub 2020 Oct 25
[PubMed PMID: 33099796]
[35]
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. The New England journal of medicine. 2018 Jun 28:378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21
[PubMed PMID: 29782224]
[36]
Elmariah SB, Smith JS, Merola JF. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety. American journal of clinical dermatology. 2022 Jul:23(4):427-431. doi: 10.1007/s40257-022-00701-3. Epub 2022 Jun 9
[PubMed PMID: 35679017]
Level 3 (low-level) evidence